Christine Esau

VP, Biology at Arrowhead Pharmaceuticals

Speaker

Christine Esau is Vice President of Biology at Arrowhead Pharmaceuticals, which develops RNA medicines that treat intractable diseases by silencing the genes that cause them. Dr. Esau has more than twenty years experience in the discovery and development of a broad range of RNA-based therapeutics utilizing multiple modalities. Previously she oversaw preclinical activities at Genevant Sciences and Arcturus Therapeutics for a portfolio of siRNA and mRNA therapeutic programs. She performed pioneering work in microRNA targeting and biology at Ionis Pharmaceuticals and Regulus Therapeutics, moving several programs for cardiometabolic and infectious disease from discovery biology to development candidate selection. Dr. Esau also served as Chief Scientific Officer of AptamiR Therapeutics, developing a microRNA-based therapy for obesity. Dr. Esau earned a B.S. degree in biology from Caltech and a Ph.D. from MIT.